Ribo Life Science submits Phase II clinical trial application for RBD1119 Injection targeting coronary artery disease

Bulletin Express05-28 06:42

On 28 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the submission of a Phase II clinical trial application for its self-developed RBD1119 Injection to the European Medicines Agency (EMA).

RBD1119 is described as a novel small-interfering RNA (siRNA) antithrombotic therapy designed to provide effective and sustained protection against thrombosis in patients with coronary artery disease (CAD) while aiming to maintain a favorable bleeding-risk profile. The company highlighted that despite widespread use of antiplatelet and anticoagulant regimens, patients with stable CAD still face meaningful residual thrombotic risk, and intensified therapy is frequently constrained by bleeding concerns.

The voluntary disclosure underscores that RBD1119 remains under clinical development. Suzhou Ribo Life Science cautions that successful completion of development and commercialisation is not guaranteed, and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181474011?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 06:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181474011","market":"us","top_or_hot":-1,"title":"Ribo Life Science submits Phase II clinical trial application for RBD1119 Injection targeting coronary artery disease","media":"Bulletin Express","content":"<p>On 28 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the submission of a Phase II clinical trial application for its self-developed RBD1119 Injection to the European Medicines Agency (EMA).</p>\n<p>RBD1119 is described as a novel small-interfering RNA (siRNA) antithrombotic therapy designed to provide effective and sustained protection against thrombosis in patients with coronary artery disease (CAD) while aiming to maintain a favorable bleeding-risk profile. The company highlighted that despite widespread use of antiplatelet and anticoagulant regimens, patients with stable CAD still face meaningful residual thrombotic risk, and intensified therapy is frequently constrained by bleeding concerns.</p>\n<p>The voluntary disclosure underscores that RBD1119 remains under clinical development. Suzhou Ribo Life Science cautions that successful completion of development and commercialisation is not guaranteed, and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ribo Life Science submits Phase II clinical trial application for RBD1119 Injection targeting coronary artery disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRibo Life Science submits Phase II clinical trial application for RBD1119 Injection targeting coronary artery disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-28 06:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 28 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the submission of a Phase II clinical trial application for its self-developed RBD1119 Injection to the European Medicines Agency (EMA).</p>\n<p>RBD1119 is described as a novel small-interfering RNA (siRNA) antithrombotic therapy designed to provide effective and sustained protection against thrombosis in patients with coronary artery disease (CAD) while aiming to maintain a favorable bleeding-risk profile. The company highlighted that despite widespread use of antiplatelet and anticoagulant regimens, patients with stable CAD still face meaningful residual thrombotic risk, and intensified therapy is frequently constrained by bleeding concerns.</p>\n<p>The voluntary disclosure underscores that RBD1119 remains under clinical development. Suzhou Ribo Life Science cautions that successful completion of development and commercialisation is not guaranteed, and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1181474011","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181474011","pubTimestamp":1779921770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 28 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the submission of a Phase II clinical trial application for its self-developed RBD1119 Injection to the European...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"日博生命科学提交RBD1119注射液靶向冠状动脉疾病的II期临床试验申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"On 28 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the submission of a Phase II clinical trial application for its self-developed RBD1119 Injection to the European Medicines Agency (EMA).\nRBD1119 is described as a novel small-interfering RNA (siRNA) antithrombotic therapy designed to provide effective and sustained protection against thrombosis in patients with coronary artery disease (CAD) while aiming to maintain a favorable bleeding-risk profile. The company highlighted that despite widespread use of antiplatelet and anticoagulant regimens, patients with stable CAD still face meaningful residual thrombotic risk, and intensified therapy is frequently constrained by bleeding concerns.\nThe voluntary disclosure underscores that RBD1119 remains under clinical development. Suzhou Ribo Life Science cautions that successful completion of development and commercialisation is not guaranteed, and advises shareholders and potential investors to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181474011","isCrawlerRequest":true}